Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK4 | P11802 | 20/20 | 0.44 |
| ▸ | CDK6 | Q00534 | 17/20 | 0.44 |
| ▸ | CDK2 | P24941 | 15/20 | 0.44 |
| ▸ | CDK1 | P06493 | 4/20 | 0.44 |
| ▸ | CDK7 | P50613 | 4/20 | 0.44 |
| ▸ | CDK9 | P50750 | 4/20 | 0.44 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | CCND3 | P30281 | 2/20 | 0.40 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.40 |
| ▸ | CSF1R | P07333 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29491157 | 0.79 | MAPT (0.45) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL22650774 | 0.79 | CDK4 (0.51) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL22650953 | 0.78 | JAK2 (0.45) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL22650859 | 0.76 | CDK4 (0.51) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL22650473 | 0.75 | MAP3K14 (0.41) | CDK2CCNA2 | |
| SCHEMBL22650549 | 0.74 | ZAP70 (0.42) | CDK2CDK1CDK9CCNA2 | |
| SCHEMBL22650734 | 0.74 | CDK6 (0.48) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL22650501 | 0.73 | CDK2 (0.40) | CDK4CDK2CDK1CDK9CCNA2 | |
| SCHEMBL22650548 | 0.72 | CDK4 (0.41) | CDK4CDK6CDK2CDK1CDK7 | |
| SCHEMBL18288761 | 0.71 | CDK4 (0.80) | CDK4CDK6CDK2CDK1CDK7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120040446-A | CDK inhibitors | 基因泰克公司 | 2025-05-27 | — | — | CN | disclosed |
| US-20220296595-A1 | CDK INHIBITORS | GENENTECH, INC. | 2022-09-22 | — | — | US | disclosed |
| CN-114364675-A | CDK inhibitors | 上海齐鲁锐格医药研发有限公司 | 2022-04-15 | — | — | CN | disclosed |
| EP-3966213-A1 | CDK INHIBITORS | Qilu Regor Therapeutics Inc. (CN) | 2022-03-16 | — | — | EP | disclosed |
| WO-2020224568-A1 | CDK INHIBITORS | QILU REGOR THERAPEUTICS INC. (CN) | 2020-11-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220296595-A1 | CDK INHIBITORS | CDKL1, CDK9, CDK6 | CDK4 10/4885CDK6 3/4885CDK2 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.